Cantor’s Elemer Piros bets on 52% upside potential for DVAX stock following its 2017 performance.
Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.
Dynavax Technologies Corporation (NASDAQ:DVAX) announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at …
After market close, Dynavax Technologies Corporation (NASDAQ:DVAX) announced that it intends to offer and sell $125.0 million of shares of its common stock, …
Valeant May Post Weak 2Q Print- But Might Not Dent Investor Sentiment After All Valeant Pharmaceuticals Intl Inc (NYSE:VRX) delivers its second-quarter print …
Valeant’s Debt Problems Continue to Be Overhangs for the Stock Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were stumbling almost 6%, having lost practically 13% …
Dynavax’s Advantage Weighs Towards Heplisav’s Benefits Dynavax Technologies Corporation (NASDAQ:DVAX) shares are racing 5% today after releasing second-quarter earnings. However, this rocket momentum …
Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the second quarter ended June 30, 2017. Cash, cash equivalents and marketable securities were $127.
William Blair analyst Y Katherine Xu is out with a bullish note on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), after the FDA’s Vaccines and Related Biological …
Dynavax Technologies Corporation (NASDAQ:DVAX) shares are skyrocketing over 70% after the FDA VRBPAC panel voted 12-1 with 3 abstentions that the safety to …
